About Nuclear pore complex-interacting protein family member A8
Nuclear pore complex-interacting protein family member A8 (NPIPA8) is a protein
from Homo sapiens identified by UniProt accession
P0DM63, 369 residues long.
MolForge cross-references it against 0 known binders and
9 disease associations.
Target properties
| Protein name | Nuclear pore complex-interacting protein family member A8 |
| UniProt accession | P0DM63 |
| Gene | NPIPA8 |
| Organism | Homo sapiens |
| Length | 369 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (9)
Diseases linked to this target (Open Targets).
- smoking status measurement · score 0.24
- visual perception measurement · score 0.23
- smoking behavior · score 0.22
- smoking initiation · score 0.18
- substance abuse · score 0.14
- antisocial behaviour measurement · score 0.14
- attention deficit hyperactivity disorder · score 0.14
- PHF-tau measurement · score 0.14
- mathematical ability · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P0DM63-F1 | alphafold | PREDICTED | 51.14 | — |
Amino-acid sequence (369 residues)
MFCCLGYEWL SGGCTTWHSA WVINTLADHR HRGTDFGGSP WLLIITVFLR SYKFAISLCT SYLCVSFLKT IFPSQNGHDG STDVQQRARR SNRRRQEGIK IVLEDIFTLW RQVETKVRAK IRKMKVTTKV NRHDKINGKR KTAKEHLRKL SMKEREHREE ERQVSEAEEN GKLDMKEIHT YMEMFQRAQA LRRRAEDYYR CKITPSARKP LCNRVRMAAV EHRHSSGLPY WPYLTAETLK NRMGHQPPPP TQQHSIIDNS LSLKTPSECV LYPLPPSADD NLKTPPECLL TPLPPSALPS ADDNLKTPAE CLLYPLPPSA DDNLKTPPEC LLTPLPPSAP PSADDNLKTP PECVCSLPFH PQRMIISRN
Explore Nuclear pore complex-interacting protein family member A8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets